Cargando…
Nanobodies Enhancing Cancer Visualization, Diagnosis and Therapeutics
Worldwide, cancer is a serious health concern due to the increasing rates of incidence and mortality. Conventional cancer imaging, diagnosis and treatment practices continue to substantially contribute to the fight against cancer. However, these practices do have some risks, adverse effects and limi...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8472690/ https://www.ncbi.nlm.nih.gov/pubmed/34575943 http://dx.doi.org/10.3390/ijms22189778 |
_version_ | 1784574799044935680 |
---|---|
author | Naidoo, Dhaneshree Bestinee Chuturgoon, Anil Amichund |
author_facet | Naidoo, Dhaneshree Bestinee Chuturgoon, Anil Amichund |
author_sort | Naidoo, Dhaneshree Bestinee |
collection | PubMed |
description | Worldwide, cancer is a serious health concern due to the increasing rates of incidence and mortality. Conventional cancer imaging, diagnosis and treatment practices continue to substantially contribute to the fight against cancer. However, these practices do have some risks, adverse effects and limitations, which can affect patient outcomes. Although antibodies have been developed, successfully used and proven beneficial in various oncology practices, the use of antibodies also comes with certain challenges and limitations (large in size, poor tumor penetration, high immunogenicity and a long half-life). Therefore, it is vital to develop new ways to visualize, diagnose and treat cancer. Nanobodies are novel antigen-binding fragments that possess many advantageous properties (small in size, low immunogenicity and a short half-life). Thus, the use of nanobodies in cancer practices may overcome the challenges experienced with using traditional antibodies. In this review, we discuss (1) the challenges with antibody usage and the superior qualities of nanobodies; (2) the use of antibodies and nanobodies in cancer imaging, diagnosis, drug delivery and therapy (surgery, radiotherapy, chemotherapy and immunotherapy); and (3) the potential improvements in oncology practices due to the use of nanobodies as compared to antibodies. |
format | Online Article Text |
id | pubmed-8472690 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-84726902021-09-28 Nanobodies Enhancing Cancer Visualization, Diagnosis and Therapeutics Naidoo, Dhaneshree Bestinee Chuturgoon, Anil Amichund Int J Mol Sci Review Worldwide, cancer is a serious health concern due to the increasing rates of incidence and mortality. Conventional cancer imaging, diagnosis and treatment practices continue to substantially contribute to the fight against cancer. However, these practices do have some risks, adverse effects and limitations, which can affect patient outcomes. Although antibodies have been developed, successfully used and proven beneficial in various oncology practices, the use of antibodies also comes with certain challenges and limitations (large in size, poor tumor penetration, high immunogenicity and a long half-life). Therefore, it is vital to develop new ways to visualize, diagnose and treat cancer. Nanobodies are novel antigen-binding fragments that possess many advantageous properties (small in size, low immunogenicity and a short half-life). Thus, the use of nanobodies in cancer practices may overcome the challenges experienced with using traditional antibodies. In this review, we discuss (1) the challenges with antibody usage and the superior qualities of nanobodies; (2) the use of antibodies and nanobodies in cancer imaging, diagnosis, drug delivery and therapy (surgery, radiotherapy, chemotherapy and immunotherapy); and (3) the potential improvements in oncology practices due to the use of nanobodies as compared to antibodies. MDPI 2021-09-10 /pmc/articles/PMC8472690/ /pubmed/34575943 http://dx.doi.org/10.3390/ijms22189778 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Naidoo, Dhaneshree Bestinee Chuturgoon, Anil Amichund Nanobodies Enhancing Cancer Visualization, Diagnosis and Therapeutics |
title | Nanobodies Enhancing Cancer Visualization, Diagnosis and Therapeutics |
title_full | Nanobodies Enhancing Cancer Visualization, Diagnosis and Therapeutics |
title_fullStr | Nanobodies Enhancing Cancer Visualization, Diagnosis and Therapeutics |
title_full_unstemmed | Nanobodies Enhancing Cancer Visualization, Diagnosis and Therapeutics |
title_short | Nanobodies Enhancing Cancer Visualization, Diagnosis and Therapeutics |
title_sort | nanobodies enhancing cancer visualization, diagnosis and therapeutics |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8472690/ https://www.ncbi.nlm.nih.gov/pubmed/34575943 http://dx.doi.org/10.3390/ijms22189778 |
work_keys_str_mv | AT naidoodhaneshreebestinee nanobodiesenhancingcancervisualizationdiagnosisandtherapeutics AT chuturgoonanilamichund nanobodiesenhancingcancervisualizationdiagnosisandtherapeutics |